Affimed announced that the first patient was dosed in a Phase 1 multicenter, open label, first-in-human dose escalation study of the innate cell engager AFM28 monotherapy in patients with CD123-positive relapsed/refractory acute myeloid leukemia. AFM28 efficiently directs natural killer cells to CD123-positive leukemic cells, including blasts and leukemic stem and progenitor cells, inducing their depletion in samples of patients with AML and myelodysplastic syndrome.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AFMD:
- Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia
- Affimed assumed with an Overweight at Wells Fargo
- Affimed price target lowered to $1 from $2 at Stifel
- Affimed Reports 2022 Financial Results and Operational Progress
- Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023
